Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acucela
Acucela’s Novel Visual Cycle Modulator Demonstrates Promise as a Treatment for Dry Age-Related Macular Degeneration
July 10th, 2009
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced that data on the company's novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (AMD), will be featured at the Aegean Retina XI Meeting being held in Crete, Greece from July 3 to 5, 2009. Dry AMD is a leading cause of vision loss in people over the age of 50, yet there are no therapies currently approved to treat this condition. "Over the next 20 years, the population of Americans over age 65 is expected to double. With this rapidly aging society, it is critical to address the significant unmet...
Source: Health Business Week (2009-07-10)
|
